UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): July 21, 2026 |
Pediatrix Medical Group, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Florida |
001-12111 |
26-3667538 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
1301 Concord Terrace |
|
Sunrise, Florida |
|
33323 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 954 384-0175 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $.01 per share |
|
MD |
|
The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported, on May 1, 2026, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”) and Ms. Mary Ann E. Moore determined that Ms. Moore would transition from her role as the Executive Vice President, General Counsel, Chief Administrative Officer and Secretary of the Company prior to the end of the calendar year. On July 21, 2026, Ms. Moore and PMG Services, Inc., a wholly-owned subsidiary of the Company (“PMG”), entered into a Separation Agreement pursuant to which Ms. Moore will serve in an advisory role to the Company until October 31, 2026 and transition from the Company effective as of such date. Ms. Moore’s transition from the Company is a termination without cause under that certain Second Amended and Restated Employment Agreement between Ms. Moore and PMG, and Ms. Moore will receive the benefits specified therein.
Item 7.01 Regulation FD Disclosure.
The Company has appointed Mr. David Haddock as Executive Vice President, General Counsel and Secretary of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Pediatrix Medical Group, Inc. |
|
|
|
|
Date: |
July 24, 2026 |
By: |
/s/ Kasandra H. Rossi |
|
|
|
Kasandra H. Rossi
Chief Financial Officer |